| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON-2015-0075 |
| P698 | PubMed publication ID | 27044592 |
| P2093 | author name string | Richard D Carvajal | |
| Daniel K Manson | |||
| Kimberly M Komatsubara | |||
| P2860 | cites work | Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors | Q24294914 |
| Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP | Q24298571 | ||
| Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas | Q24303940 | ||
| Mutations in GNA11 in uveal melanoma | Q24625723 | ||
| Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi | Q24646052 | ||
| Oncogenic mutations in GNAQ occur early in uveal melanoma | Q24658558 | ||
| Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer | Q27666699 | ||
| Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973) | Q27684146 | ||
| Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers | Q27685364 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 | ||
| Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial | Q27851856 | ||
| MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study | Q27852083 | ||
| Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells | Q27853016 | ||
| Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial | Q27853021 | ||
| Combined vemurafenib and cobimetinib in BRAF-mutated melanoma | Q27853076 | ||
| Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance | Q28282963 | ||
| Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 | ||
| Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma | Q28543960 | ||
| Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 | ||
| Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). | Q30384829 | ||
| The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society | Q31995716 | ||
| Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. | Q33819083 | ||
| Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity | Q33971120 | ||
| A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer | Q34106382 | ||
| Therapeutic implications of the emerging molecular biology of uveal melanoma. | Q34173920 | ||
| Incidence of noncutaneous melanomas in the U.S. | Q34554179 | ||
| Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma | Q34633455 | ||
| Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study | Q34652628 | ||
| Genomic Classification of Cutaneous Melanoma | Q34670776 | ||
| Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice | Q35096292 | ||
| Incidence of uveal melanoma in the United States: 1973-1997. | Q35128733 | ||
| A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors | Q35563528 | ||
| Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma | Q35812275 | ||
| The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models | Q35835097 | ||
| Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations | Q35915107 | ||
| Targeting the mitogen-activated protein kinase cascade to treat cancer | Q35968411 | ||
| Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma | Q36612452 | ||
| Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. | Q36615986 | ||
| Galphaq binds two effectors separately in cells: evidence for predetermined signaling pathways | Q36838853 | ||
| Mitogenic signaling pathways induced by G protein-coupled receptors | Q36929839 | ||
| Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience | Q37701881 | ||
| Uveal melanoma: trends in incidence, treatment, and survival | Q37894345 | ||
| Tumor adaptation and resistance to RAF inhibitors | Q38160738 | ||
| Treatment of NRAS-mutant melanoma. | Q38386344 | ||
| Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer | Q38445646 | ||
| MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road | Q38591835 | ||
| Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death | Q39188117 | ||
| Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner | Q39325158 | ||
| Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition | Q39442875 | ||
| GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition | Q39606314 | ||
| MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies for KRAS Mutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy | Q39625657 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| Galphaq binds to p110alpha/p85alpha phosphoinositide 3-kinase and displaces Ras. | Q40355032 | ||
| Regulation of Raf-1 by direct feedback phosphorylation. | Q40467820 | ||
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial | Q40875359 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers | Q43136770 | ||
| The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer | Q43152544 | ||
| Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma | Q43154862 | ||
| The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK. | Q43297233 | ||
| High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma | Q43509621 | ||
| Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea | Q43998617 | ||
| Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma | Q44004637 | ||
| Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 | ||
| The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel | Q46825496 | ||
| The RAS-BRAF kinase pathway is not involved in uveal melanoma | Q47390207 | ||
| Very long-term prognosis of patients with malignant uveal melanoma | Q47423812 | ||
| Lack of BRAF mutation in primary uveal melanoma. | Q47807462 | ||
| Activation of Akt/protein kinase B by G protein-coupled receptors. A role for alpha and beta gamma subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinasegamma. | Q47828172 | ||
| First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. | Q54499836 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | uveal melanoma | Q356372 |
| P304 | page(s) | 1331-1344 | |
| P577 | publication date | 2016-04-05 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives | |
| P478 | volume | 12 |
| Q47223959 | Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas. |
| Q51418687 | GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma |
| Q64949664 | Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations. |
| Q47655869 | ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells |
| Q92458965 | Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma |
| Q47708657 | Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics. |
| Q89337067 | Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma |
Search more.